- Report
- December 2022
- 115 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- August 2022
- 110 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Drug Pipelines
- October 2020
- 773 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Drug Pipelines
- September 2020
- 35 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Drug Pipelines
- January 2019
- 163 Pages
Global
From €20024EUR$22,000USD£17,007GBP
- Report
- July 2018
- 14 Pages
Global
From €9102EUR$10,000USD£7,731GBP
- Report
- August 2022
- 580 Pages
Global
From €2275EUR$2,500USD£1,933GBP
- Report
- May 2022
- 40 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Report
- May 2022
- 40 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Book
- March 2015
- 512 Pages
Thrombolytics are a class of cardiovascular drugs used to treat acute ischemic stroke, myocardial infarction, and pulmonary embolism. They work by breaking down the clot that is blocking the blood vessel, allowing blood to flow freely. Thrombolytics are typically administered intravenously, and can be used in combination with other treatments such as anticoagulants and antiplatelet drugs. The most commonly used thrombolytic is tissue plasminogen activator (tPA), which is a recombinant form of the naturally occurring enzyme plasminogen.
The thrombolytics market is highly competitive, with a number of companies offering products for the treatment of cardiovascular diseases. Some of the major players in the market include Boehringer Ingelheim, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. Show Less Read more